BETHESDA, Md., Aug. 03, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) is pleased to announce the publication of “Marijuana Could Help Treat Alzheimer’s: Here’s How It Would Work” on August 1, 2017 by Javier Hasse on the website of “HIGH TIMES.”
IGC’s CEO, Ram Mukunda and IGC’s key advisor, Dr. Chuanhai Cao were quoted with respect to the potential therapeutic effects of THC on Alzheimer’s Disease.
“In Alzheimer’s Disease, beta-amyloid aggregates into a plaque-like substance that builds around the neurons and disrupts communication between them. So of course, if low-doses of THC can break up those plaques and prevent them from forming in the first place, it’s a huge breakthrough,” stated Ram Mukunda, CEO.
“The paper argued that therapeutic, low [non-psychoactive] doses of THC (one of the main chemical compounds present in marijuana) could directly bind to a protein called amyloid-beta, preventing its aggregation and thereby slowing down the formation of amyloid-beta plaques around neurons,” Dr. Chuanhai Cao, a professor of neurology and pharmacy at the University of South Florida’s Byrd Institute for Alzheimer’s.
The associated link for the full article can be found at: http://hightimes.com/medicinal/marijuana-could-help-treat-alzheimers-heres-how-it-would-work/
As previously reported, IGC entered into a definitive license agreement with the University of South Florida making IGC the exclusive licensee of the U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.”
By acquiring this patent filing, IGC is protecting a potential cannabis-based blockbuster treatment for America’s most expensive disease.
About HIGH TIMES
HIGH TIMES is the definitive resource for all things cannabis. From cultivation and legalization, to entertainment and culture, to hard-hitting news exposing the War on Drugs, HIGH TIMES has been the preeminent source for cannabis information since 1974.
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in humans, dogs and cats. In support of this effort, IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.
For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.